Prevention · 8 min read · Updated March 2026

Aspirin for Colorectal Cancer Prevention: The 15-20% Risk Reduction (And When It Backfires)

Low-dose aspirin reduces colorectal cancer risk by 15-20% with long-term use. But the ASPREE trial found increased cancer mortality in adults over 70. Age and timing matter.

🔬 Grade B: Promising

The Bottom Line

Low-dose aspirin (75-100mg daily) reduces colorectal cancer risk by approximately 15-20% with long-term use (5+ years). This is supported by multiple randomized trials, meta-analyses, and the US Preventive Services Task Force (USPSTF) previously recommended aspirin for CRC prevention in specific populations. However, the ASPREE trial (2018) complicated things: in adults over 70, aspirin was associated with increased cancer mortality. The benefit appears age-dependent: strongest when started in your 40s-50s, potentially harmful when started after 70.

The Evidence for Colorectal Cancer

  • Rothwell meta-analysis (Lancet 2010, 2012): Pooling multiple RCTs, aspirin reduced CRC incidence by ~24% and CRC mortality by ~35% with 5+ years of use
  • Nurses' Health Study + Health Professionals Follow-up Study: Regular aspirin use associated with 19% lower CRC risk
  • CAPP2 trial (Lynch syndrome): 600mg aspirin daily reduced cancer incidence by 63% in people with Lynch syndrome (hereditary CRC predisposition). This is the strongest signal in a genetically defined population.
  • Mechanism: Aspirin inhibits COX-2 (cyclooxygenase-2), which is overexpressed in colorectal tumors and promotes prostaglandin E2-driven inflammation, cell proliferation, and angiogenesis. Aspirin also activates AMPK and has platelet-mediated anti-metastatic effects.

The ASPREE Problem

The ASPREE trial (ASPirin in Reducing Events in the Elderly) enrolled 19,114 adults aged 70+ and randomized them to aspirin 100mg daily vs. placebo:

  • Surprising finding: Aspirin was associated with higher cancer mortality (HR 1.31) in the overall population
  • Possible explanation: Aspirin may promote bleeding into existing undiagnosed tumors, or the age-related immune changes may interact differently with aspirin's anti-inflammatory effects
  • Key takeaway: Starting aspirin after 70 for cancer prevention appears harmful. The benefit is in starting earlier.

Who Benefits

  • Adults 40-59 with 10+ year life expectancy: The USPSTF previously found net benefit for CRC prevention in this group (though they've since softened the recommendation)
  • Lynch syndrome carriers: Strong evidence (CAPP2 trial) for cancer risk reduction
  • People with personal or family history of colorectal adenomas: Aspirin reduces adenoma recurrence
  • People already taking aspirin for cardiovascular prevention: The cancer benefit is an added bonus

Who Should NOT Take Aspirin for Cancer Prevention

  • Adults over 70 without existing cardiovascular indication (ASPREE signal)
  • People with bleeding disorders or on anticoagulants
  • History of GI bleeding or peptic ulcer disease
  • Aspirin allergy
  • Uncontrolled hypertension (increases bleeding risk)

Practical Protocol

  • Dose: 75-100mg daily (standard "baby aspirin" or low-dose)
  • Duration: Benefits for CRC prevention appear after 5+ years of consistent use
  • Starting age: 40-59 appears optimal. Discuss with your physician.
  • Stopping age: Consider stopping at 70 unless cardiovascular indication remains
  • GI protection: Consider enteric-coated formulation. PPI co-prescription may be warranted in high-risk individuals.
  • Cost: ~$3/month

Our Assessment

Aspirin for colorectal cancer prevention is one of the few interventions with Phase III RCT-level evidence showing meaningful risk reduction. The 15-20% reduction in CRC with long-term use is real and replicated. The CAPP2 data in Lynch syndrome is even more compelling. But ASPREE introduced important nuance: age matters. The ideal window appears to be starting in your 40s-50s and potentially stopping after 70. This is a conversation to have with your physician, weighing your individual cardiovascular and bleeding risk. For the right patient, low-dose aspirin is one of the most cost-effective cancer prevention tools available.

Sources

  • Lancet 2010;376:1741-50: Rothwell et al. aspirin and long-term cancer incidence
  • Lancet 2012;379:1602-12: Rothwell et al. short-term effects of daily aspirin on cancer
  • NEJM 2018;379:1509-18: ASPREE trial results
  • Lancet 2011;378:2081-87: CAPP2 trial (Lynch syndrome)
  • USPSTF Aspirin Use recommendation (2022 update)

Related Research

Medical Disclaimer: This is a research review, not medical advice. Always consult with qualified healthcare professionals before making any changes to your health regimen.

How we grade evidence: Grade A = Phase II+ RCT with positive signal. Grade B = Phase I/II or strong epidemiology. Grade C = Preclinical only. Debunked = Retracted or disproven. Full methodology →